Many laboratory strains of Escherichia coli are resistant to methotrexate (MTX), a folate analogue that binds dihydrofolate reductase (DHFR). Mutations that inactivate either tolC or acrA confer MTX sensitivity. Further, overexpression of a fusion protein with DHFR activity reverses this sensitivity by titrating out intracellular MTX. These results suggest that MTX accumulates in cells where mutations in acrA or tolC have inactivated the TolC-dependent AcrAB multidrug resistance efflux pump.
Methotrexate (MTX) is a folate analogue that inhibits the activity of dihydrofolate reductase (DHFR) (16) , which catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate. Reduced folates are substrates in a number of one-carbon transfers in purine, pyrimidine, and amino acid biosynthesis (3) . Inhibition of DHFR activity initially results in the depletion of N 5 ,N 10 -methylene tetrahydrofolate, followed by inhibition of DNA synthesis and ultimately cell death (8) . DHFR is thus a well-studied target of antibiotic and antineoplastic therapy.
Although MTX binds both human and Escherichia coli DHFR very tightly, with K i values of 3.4 and 1.0 pM, respectively (2) , all of the E. coli isolates we tested (genotypes of the strains used in this study are listed in Table 1 ), which included both common laboratory strains (MG1655, MC4100, AG1688, and ZK126) and clinical isolates (O157:H7, RM74A, STM1, LL, RM52B, DD, and RM33B), were resistant to MTX added to solid medium at concentrations of up to 1 mM, the highest concentration we tested (data not shown).
Antibiotic resistance can occur by a variety of mechanisms, including failure of the drug to bind its target, overexpression of the drug target, modification or degradation of the drug, creation of permeability barriers, or active export of the drug. It is increasingly recognized that active efflux plays a major role in the resistance of many organisms to a plethora of agents (11, 20) . A wide variety of antibiotics are exported from E. coli by one of several active efflux systems (11, 12, 19, 20) . At least two of these systems, the AcrAB and EmrAB efflux pumps, have been shown to depend on the outer membrane protein TolC (1, 7, 12, 19, 20) .
To determine whether the MTX resistance was due to a TolC-dependent efflux pump, we examined the effect of a tolC::Tn10 mutation. LBB1175, in which tolC had been inactivated by the Tn10 insertion, was sensitive to 1 mM MTX, while W4573, the isogenic TolC ϩ control, was resistant. Similar results were obtained using the common laboratory strain MG1655, which is the reference wild-type E. coli K-12 strain used for the genome sequence (4), and AG1688 (see below). Strains carrying Tn10 at a different chromosomal location remained resistant to MTX. These results suggest that MTX resistance is mediated by a TolC-containing multidrug resistance efflux pump (MDR).
tolC mutants are pleiotropic (17, 26) and are hypersensitive to many hydrophobic agents (18) . Thus, the loss of MTX resistance in the tolC mutant might not be due to the loss of function of an MDR. To address this possibility, we tested the effects of mutations that inactivate specific TolC-dependent MDRs. The AcrAB pump belongs to the RND (for resistance, nodulation, and division) family, and its substrates include sodium dodecyl sulfate, basic dyes, novobiocin, and tetracycline (19, 20) ; the EmrAB pump belongs to the MF (major facilitator) family, and its substrates include carbonyl cyanide m-chlorophenylhydrazone, nalidixic acid, and phenyl mercury acetate (19, 20) . A strain containing the acrA1 mutation (N43) was sensitive to 1 mM MTX, while its isogenic parent (W4573) was resistant. In contrast, both the emrB mutant (OLS103) and its isogenic parent (AMS6) were MTX resistant. These results show that the MTX sensitivity of the tolC strains is at least partly due to inactivation of the AcrAB MDR, while the EmrAB pump does not have a major role in MTX export.
MICs of MTX were determined for a set of isogenic E. coli strains containing combinations of acrA, emrB, and tolC mutations ( Table 2 ). The wild-type strain (W4573) was resistant to 1,024 M MTX, the highest concentration tested. The emrB mutation did not affect the MIC, either alone (compare W4573 to SK636) or in combination with acrA1 (compare N43 to SK627) or tolC::Tn10 (compare SK642 to SK660). Inactivation of either acrA or tolC resulted in a decrease of the MTX MIC to 256 or 64 M, respectively. Since the acrA1 allele is an IS2 insertion in the second codon of acrA (14) , it is unlikely that the remaining MTX resistance in the acrA1 mutant is due to residual activity of the acrA gene product. The tolC gene product seems to have more than one role in MTX resistance. It is unclear if this is due to the loss of function of another, unidentified TolC-containing MDR or the highly pleiotropic effects of tolC mutations on outer membrane structure (17, 26) . Similar alterations have not been found in the outer membrane of acr mutants (19, 21, 24) .
The additional role of TolC is not related to the EmrAB MDR, since the acrA1 emrB double mutation (in SK627) yielded an MIC identical to that yielded by the acrA1 single mutation. Similar combinations of mutations in a different background (AG1688) yielded identical MICs (data not shown). This further demonstrates that the observed effects are not strain specific.
To determine whether inhibition of DHFR was sufficient to explain the MTX sensitivity of tolC strains, we examined whether the MTX sensitivity of AG1688 tolC::Tn10 (SK037) could be suppressed by overexpression of DHFR activity. In the course of other (unpublished) studies, we had constructed a plasmid, pSK029, which expresses a fusion protein, cI-DHFR, in which the N-terminal DNA binding domain of the bacteriophage repressor is fused to E. coli DHFR; the fusion protein is expressed under the control of the lacUV5 promoter. Neither pSK029 nor pXZ020, a control plasmid expressing cI-GCN4 (a fusion to the leucine zipper of GCN4), affected the MTX resistance of wild-type AG1688 whether or not the fusion proteins were overexpressed ( Table 3 , lines 3 and 5). AG1688 tolC::Tn10 strains containing either plasmid were sensitive to MTX under conditions in which the fusion proteins were uninduced ( Table 3 , lines 4 and 6). However, in the presence of isopropyl-␤-D-thiogalactopyranoside (IPTG), which induces the overexpression of cI-DHFR, SK029 tolC::Tn10 was resistant to high concentrations of MTX (Table  3 , line 4). In contrast, IPTG-induced overexpression of the control protein cI-GCN4 had no protective effect on the tolC strain ( Table 3, 
line 6).
These results show that MTX sensitivity in the tolC strain is due to the inhibition of endogenous DHFR by the drug. When cI-DHFR is overexpressed, the DHFR activity provided by the DHFR domain in the fusion protein cannot be titrated out, which strongly suggests that the plasmid-coded DHFR acts to sequester MTX that is added to the medium. Increasing the level of DHFR should not relieve sensitivity due to mechanisms that do not involve uptake of MTX.
The results of this study can be summarized as follows. (i) All of the TolC ϩ AcrA ϩ strains of E. coli we tested were resistant to at least 1 mM MTX when grown on solid medium containing the drug. (ii) MTX resistance is decreased by mutations that disrupt tolC or acrA, genes that code for integral components of the AcrAB MDR, suggesting that resistance is due to active export of MTX via the AcrAB MDR. (iii) Mutation of the emrB gene does not decrease MTX resistance, suggesting that MTX is not a substrate of this MDR. (iv) The difference between the MICs for tolC::Tn10 and acrA::IS2 AG1688(pSK029) pSK029, a pBR322-derived plasmid that expresses a cI-E. coli DHFR fusion protein from P lac UV5, was introduced by M13-mediated transduction (25) into AG1688 XZ020 AG1688(pXZ020) pXZ020, a pBR322-derived plasmid that expresses a cI-GCN4 leucine zipper fusion protein from P lac UV5, was introduced by M13-mediated transduction into AG1688 
